Drug Trial Radar · NCT00300482
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
Last checked: Nov 20, 2026Latest source record: Jun 10, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,445
Actual
Start
Mar 2006
Primary completion
Dec 2006
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Mar 9, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + rosuvastatin calcium combination therapy with ABT-335 and rosuvastatin calcium monotherapy in subjects with multiple abnormal lipid levels in the blood.
Conditions
- Dyslipidemia
- Coronary Heart Disease
- Mixed Dyslipidemia
Interventions
ABT-335Drug
135 mg, daily, 12 weeks
Rosuvastatin CalciumDrug
Daily, 12 weeks, see Arm Description for dosage information
PlaceboDrug
Daily, 12 weeks, see Arm Description for information regarding placebo type
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Percent Change in Triglycerides From Baseline to Final VisitTime frame: Baseline to 12 Weeks
- Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Final VisitTime frame: Baseline to 12 Weeks
- Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final VisitTime frame: Baseline to 12 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Global Medical Information
North Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.